Search
Search
About
Log in
Join
Experiences with
Idelalisib
Posts
Communities
141 public posts
Filter results
Treatment With PI3K Inhibitors Is Associated With a Number of Adverse Events and Toxicities
The pooled risk ratio of sepsis in the PI3K inhibitor group was statistically significant at 2.68, with a 2.88% higher sepsis rate in the patients treated with the PI3K inhibitor,
idelalisib
.
The pooled risk ratio of sepsis in the PI3K inhibitor group was statistically significant at 2.68, with a 2.88% higher sepsis rate in the patients treated with the PI3K inhibitor,
idelalisib
.
Jm954
Administrator
in
CLL Support
4 years ago
Combining P13K inhibitors with Keto diet for cancer.
In 2014, FDA approved the first PI3K inhibitor,
idelalisib
(Zydelig®), to treat patients with relapsed follicular lymphoma. Copanlisib (Aliqopa} is now the second approved PI3K inhibitor.
In 2014, FDA approved the first PI3K inhibitor,
idelalisib
(Zydelig®), to treat patients with relapsed follicular lymphoma. Copanlisib (Aliqopa} is now the second approved PI3K inhibitor.
MateoBeach
in
Advanced Prostate Cancer
4 years ago
My good news and more research news from EHA and iwCLL
Danilov discusses his findings related to our co-morbidities: https://cllsociety.org/2019/11/eha-2019-dr-alexey-danilov-discusses-
idelalisib
-and-comorbidities-in-cll-chronic-lymphocytic-leukemia-patients/ The phase III Alliance A041202 collaborative multi-centered trial demonstrated once and for all
Danilov discusses his findings related to our co-morbidities: https://cllsociety.org/2019/11/eha-2019-dr-alexey-danilov-discusses-
idelalisib
-and-comorbidities-in-cll-chronic-lymphocytic-leukemia-patients/ The phase III Alliance A041202 collaborative multi-centered trial demonstrated once and for all
bkoffman
CLL CURE Hero
in
CLL Support
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Follicular Lymphoma Patient: 8-Year Treatment Experience
Then she took
Idelalisib
/rituximab as her fourth treatment. It worked great for 14 months then a PET scan showed she progressed again. She is in an NIH CAR-T trial NCT02659943 was infused on March 2, 2016 (0.6e6 CAR-T cells per kg body weight).
Then she took
Idelalisib
/rituximab as her fourth treatment. It worked great for 14 months then a PET scan showed she progressed again. She is in an NIH CAR-T trial NCT02659943 was infused on March 2, 2016 (0.6e6 CAR-T cells per kg body weight).
wmay13241
in
Non Hodgkin's Lymphoma Friends
5 years ago
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
In the future, combination with new drugs such as ibrutinib, venetoclax, and
idelalisib
, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.
In the future, combination with new drugs such as ibrutinib, venetoclax, and
idelalisib
, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.
Jm954
Administrator
in
CLL Support
5 years ago
YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success
No common resistance-associated mutations or deregulated signaling pathways have been reported in
idelalisib
failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax.
No common resistance-associated mutations or deregulated signaling pathways have been reported in
idelalisib
failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax.
AussieNeil
Administrator
in
CLL Support
4 years ago
New Years Good News
Mine involves first-line treatment in a clinical trial, spectacular failure on
idelalisib
, relapse, spread of CLL to the central nervous system (complete with seizures and permanent partial blindness), good response to brain chemo for the CLL, and subsequent intolerance of ibrutinib.
Mine involves first-line treatment in a clinical trial, spectacular failure on
idelalisib
, relapse, spread of CLL to the central nervous system (complete with seizures and permanent partial blindness), good response to brain chemo for the CLL, and subsequent intolerance of ibrutinib.
Eagle5327
in
CLL Support
5 years ago
Ibrutinib linked to invasive fungal infections
In the past
Idelalisib
(Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels.
In the past
Idelalisib
(Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels.
lankisterguy
Volunteer
in
CLL Support
6 years ago
MUST READ for those on Ibrutinib/Imbruvica - concerning advice in pilot study on lower dosing - incl. danger of starting with a lower dose
BCR antagonists, likely ibrutinib, acalabrutinib,
idelalisib
, all inhibit their target kinase at a level that is dependent upon their concentration in the serum. Currently, most agents are dosed well above the necessary level to achieve 100% inhibition.
BCR antagonists, likely ibrutinib, acalabrutinib,
idelalisib
, all inhibit their target kinase at a level that is dependent upon their concentration in the serum. Currently, most agents are dosed well above the necessary level to achieve 100% inhibition.
AussieNeil
Administrator
in
CLL Support
6 years ago
CLL Treatment Sequencing by Dr. Susan O'Brien
If a patient is refractory to ibrutinib, the FDA-approved combination of
idelalisib
and rituximab (Rituxan) could be an effective second option, she added.
If a patient is refractory to ibrutinib, the FDA-approved combination of
idelalisib
and rituximab (Rituxan) could be an effective second option, she added.
lankisterguy
Volunteer
in
CLL Support
6 years ago
CLLSA and Leukaemia Care Joint Response to NHS England regarding Ibrutinib Prescribing as per NICE TA
guidance for ibrutinib use prevents patients failing
Idelalisib
from treatment with ibrutinib unless the patient fails due to
Idelalisib
related toxicity within six months of commencement of treatment.
guidance for ibrutinib use prevents patients failing
Idelalisib
from treatment with ibrutinib unless the patient fails due to
Idelalisib
related toxicity within six months of commencement of treatment.
Jm954
Administrator
in
CLL Support
6 years ago
need help - Idelalisib
I start
Idelalisib
rituxsan this week. I'm 90% bone marrow infiltrated (a long story) and 11q deleted. I'm scared and resigned, feel foolish and angry - lots of things. Where do I stand at this point? What does it mean to be 100% infiltrated?
I start
Idelalisib
rituxsan this week. I'm 90% bone marrow infiltrated (a long story) and 11q deleted. I'm scared and resigned, feel foolish and angry - lots of things. Where do I stand at this point? What does it mean to be 100% infiltrated?
springie
in
CLL Support
6 years ago
Good bye zydelig (idelalisib)
I've officially been taken off zydelig after 27 months! I think it might be some kind of record. The side effects were starting to multiply almost daily. Of course I had loose bowels for many months but I learned to cope. Five months ago I got a cough that wouldn't go away. About two week back I had
I've officially been taken off zydelig after 27 months! I think it might be some kind of record. The side effects were starting to multiply almost daily. Of course I had loose bowels for many months but I learned to cope. Five months ago I got a cough that wouldn't go away. About two week back I had
R-16728
in
Non Hodgkin's Lymphoma Friends
7 years ago
Here we go again!
Two years ago I began taking
idelalisib
as part of a trial. My life returned to normal until about two months ago when my WBC and lymphocyte counts began to climb. Now I've reached a crossroads again.
Two years ago I began taking
idelalisib
as part of a trial. My life returned to normal until about two months ago when my WBC and lymphocyte counts began to climb. Now I've reached a crossroads again.
R16728
in
Non Hodgkin's Lymphoma Friends
7 years ago
I've just reviewed treatments and am more confused!
- acalabrutinib is less toxic and 2nd-generation but availability is uncertain - other "TGR-1202 (PI3K inhibitors)" are in the pipeline (I've noted
idelalisib
, duvelisib and ofatumumab but have no idea what these do, how effective they may be, or what the long-term effects are because they're so new.
- acalabrutinib is less toxic and 2nd-generation but availability is uncertain - other "TGR-1202 (PI3K inhibitors)" are in the pipeline (I've noted
idelalisib
, duvelisib and ofatumumab but have no idea what these do, how effective they may be, or what the long-term effects are because they're so new.
deveritt
in
CLL Support
7 years ago
idelalisib
Has anyone taken this for Nfl? If so, how is it and how are the side effects?
Has anyone taken this for Nfl? If so, how is it and how are the side effects?
CarenR
in
Non Hodgkin's Lymphoma Friends
7 years ago
CAR-T Clinical Trial
Then she took
Idelalisib
/rituximab as her fourth treatment. It worked great for 14 months then a PET scan showed she progressed again. She is now in an NIH CAR-T trial NCT02659943 was infused on March 2, 2016. She has been in complete remission for 13 months.
Then she took
Idelalisib
/rituximab as her fourth treatment. It worked great for 14 months then a PET scan showed she progressed again. She is now in an NIH CAR-T trial NCT02659943 was infused on March 2, 2016. She has been in complete remission for 13 months.
wmay13241
in
Understanding Clinical Trials
7 years ago
CLL Treatment - Give your body a rest?
There is an informal paper from ASH 2015, where the question was asked “What happens when CLL Patients stop taking Ibrutinib or
Idelalisib
.”
There is an informal paper from ASH 2015, where the question was asked “What happens when CLL Patients stop taking Ibrutinib or
Idelalisib
.”
MartyR
in
CLL Support
7 years ago
Zydelig (idelalisib) my wonder drug
I'm reposting my story in hopes of catching up with more folks that have been using this drug. I've been 8 years living with Follicular Lymphoma and have had two series of chemotherapies. The first gave me 5 years remission, the second worked but my body couldn't recover quick enough to take successive
I'm reposting my story in hopes of catching up with more folks that have been using this drug. I've been 8 years living with Follicular Lymphoma and have had two series of chemotherapies. The first gave me 5 years remission, the second worked but my body couldn't recover quick enough to take successive
R-16728
in
Non Hodgkin's Lymphoma Friends
7 years ago
Zydelig (idelalisib) first line... NO!
I have had a few emails and PMs asking about the use of Zydelig (
idelalisib
) for first line, since patients know I'm on this combined with rituxan. I direct you to the newly revised drug label, which states...
I have had a few emails and PMs asking about the use of Zydelig (
idelalisib
) for first line, since patients know I'm on this combined with rituxan. I direct you to the newly revised drug label, which states...
Cllcanada
Top Poster CURE Hero
in
CLL Support
7 years ago
1
2
3
...
8
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
131 results
Non Hodgkin's Lymphoma Friends
6 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest